Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $5.92.
Several research analysts have weighed in on the stock. Raymond James dropped their price objective on shares of Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 22nd. Berenberg Bank initiated coverage on shares of Ginkgo Bioworks in a report on Monday, November 28th. They set a “buy” rating and a $6.00 price target on the stock. BTIG Research decreased their price objective on shares of Ginkgo Bioworks to $4.00 in a report on Thursday, November 17th. Finally, Morgan Stanley initiated coverage on shares of Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 target price on the stock.
Insiders Place Their Bets
In related news, major shareholder Barry Canton sold 196,721 shares of the business’s stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $2.47, for a total transaction of $485,900.87. Following the completion of the transaction, the insider now owns 24,362,523 shares of the company’s stock, valued at approximately $60,175,431.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Jason R. Kelly sold 246,449 shares of the business’s stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $1.61, for a total transaction of $396,782.89. Following the completion of the transaction, the insider now owns 16,734,634 shares of the company’s stock, valued at approximately $26,942,760.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Barry Canton sold 196,721 shares of the business’s stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $2.47, for a total value of $485,900.87. Following the transaction, the insider now directly owns 24,362,523 shares of the company’s stock, valued at approximately $60,175,431.81. The disclosure for this sale can be found here. Insiders sold 7,669,071 shares of company stock valued at $16,878,340 over the last quarter. Insiders own 17.47% of the company’s stock.
Hedge Funds Weigh In On Ginkgo Bioworks
Ginkgo Bioworks Stock Up 1.1 %
Ginkgo Bioworks stock opened at $1.86 on Tuesday. The firm has a market cap of $3.61 billion, a PE ratio of -0.81 and a beta of 0.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71. The firm’s 50 day moving average price is $1.89 and its two-hundred day moving average price is $2.55. Ginkgo Bioworks has a twelve month low of $1.45 and a twelve month high of $6.42.
Ginkgo Bioworks (NYSE:DNA – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $66.40 million during the quarter, compared to analyst estimates of $54.28 million. Ginkgo Bioworks had a negative net margin of 668.49% and a negative return on equity of 85.90%. On average, research analysts predict that Ginkgo Bioworks will post -1.41 EPS for the current fiscal year.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.